CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit upZhitong·Sep 24, 2025 at 08:55 PM000739+1.00%603456+1.25%
Zhitong A-share lock-up release overview | September 2Zhitong·Sep 1, 2025 at 08:01 PM0023400.00%301296+1.46%
OPM: Expected net profit of approximately 37 million yuan in the first half of the year, a year-on-year increase of 53.28%Zhitong·Jul 13, 2025 at 03:11 AM688293-2.72%
The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suitZhitong·Jun 26, 2025 at 01:17 AM688293-2.72%688488+2.22%
OPM plans to issue shares to acquire 100% equity of Pengli Bio at a transaction price of 1.451 billion yuanZhitong·Jun 5, 2025 at 11:49 AM688293-2.72%
OPM released its first-quarter performance, with a net profit attributable to the parent company of 14.67 million yuan, a year-on-year decrease of 25.08%Zhitong·Apr 28, 2025 at 05:34 AM688293-2.72%
OPM released its 2024 annual performance, with a net profit attributable to the parent company of 21.0523 million yuan, a year-on-year decrease of 61.04%Zhitong·Apr 15, 2025 at 07:02 AM688293-2.72%
OPM shareholder Huajie Investment has completed a 3% share reductionZhitong·Apr 1, 2025 at 04:59 AM688293-2.72%
OPM's major shareholder Huajie Investment reduced its holdings by 1.124 million sharesZhitong·Mar 11, 2025 at 05:33 AM688293-2.72%
OPM's net profit for the year 2024 is 21.1267 million yuan, a year-on-year decrease of 60.9%Zhitong·Feb 27, 2025 at 01:51 AM688293-2.72%
OPM shareholders Shanghai Panxin have cumulatively reduced their holdings in the company by 2.63%Zhitong·Feb 23, 2025 at 07:31 AM688293-2.72%
OPM shareholders Shanghai Panxin have cumulatively reduced their holdings in the company by 1%Zhitong·Feb 14, 2025 at 03:24 AM688293-2.72%
OPM shareholders Huajie Investment and Shanghai Panxin have cumulatively reduced their holdings by 2.0115 million sharesZhitong·Feb 11, 2025 at 03:50 AM688293-2.72%
OPM plans to issue additional shares to acquire 100% equity of CRO company Pengli Biotechnology to enhance its overseas influence, resuming trading on February 10Zhitong·Feb 7, 2025 at 03:40 AM688293-2.72%
